Personalis (PSNL) and Tempus AI (TEM) said Monday they have expanded their collaboration to the biopharma industry.
Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.
The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.
Price: 3.90, Change: +0.08, Percent Change: +2.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments